Table 2.

Serum concentration of sunitinib plus N-desethyl sunitinib, sunitinib, N-desethyl sunitinib, and sunitinib N-oxide by time after initiation of sunitinib treatment in individual patients receiving long-term sunitinib treatment

	Serum concentration (ng/mL) after initiation of sunitinib treatment
	0–210 days		211–420 days		421–630 days		631–840 days		841–1050 days		1051–1260 days		1261–1470 days		1471–1680 days		1681–1890 days		1891–2100 days
	Mean		Mean		Mean		Mean		Mean		Mean		Mean		Mean		Mean		Mean
Sunitinib + N-desethyl sunitinib
Pt1					53.0		59.3		51.7		42.7		33.2
Pt2							109.5		94.4
Pt3											72.7		67.3		79.5		68.7
Pt4																			65.4
Pt5													54.8		56.8		54.1
Pt6	101.4		93.5		67.9
Pt7	48.9
Sunitinib
Pt1					44.0		48.3		41.2		33.1		26.2
Pt2							86.7		73.5
Pt3											59.5		54.9		64.1		54.1
Pt4																			54.5
Pt5													42.2		44.7		39.4
Pt6	71.0		65.8		37.5
Pt7	31.1
N-desethyl sunitinib
Pt1					9.0		11.0		10.4		9.6		6.9
Pt2							22.7		20.9
Pt3											13.2		12.5		15.5		14.6
Pt4																			11.0
Pt5													12.6		12.1		14.7
Pt6	30.4		27.7		30.4
Pt7	17.8
Sunitinib N-oxide
Pt1					0.68		0.59		0.40		0.29		0.10
Pt2							1.10		0.71
Pt3											0.99		0.58		0.53		0.32
Pt4																			1.35
Pt5													0.56		0.57		0.36
Pt6	0.56		0.55		0.17
Pt7	0.24